{"id":2087,"date":"2021-05-11T13:10:00","date_gmt":"2021-05-11T13:10:00","guid":{"rendered":"https:\/\/preprod.treefrog.fr\/?p=2087"},"modified":"2021-07-20T14:46:37","modified_gmt":"2021-07-20T14:46:37","slug":"c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells","status":"publish","type":"post","link":"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/","title":{"rendered":"C-Stem\u2122 outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

La technologie biomim\u00e9tique de TreeFrog Therapeutics repousse les limites de la production industrielle de th\u00e9rapies cellulaires issues de cellules souches. La soci\u00e9t\u00e9 vient de produire un lot de 15 milliards de cellules souches, avec une croissance exponentielle in\u00e9dite dans des bior\u00e9acteurs de 10 litres, tout en maintenant un haut niveau de qualit\u00e9.<\/strong><\/p>

Bordeaux, France \u2013 13 avril 2021.<\/strong> La biotech fran\u00e7aise de th\u00e9rapie cellulaire TreeFrog Therapeutics<\/a> annonce \u00eatre parvenue \u00e0 cultiver des cellules souches pluripotentes induites humaines (hiPSC) dans un bior\u00e9acteur de 10 litres, avec un facteur d’amplification sans pr\u00e9c\u00e9dent. Gr\u00e2ce \u00e0 sa technologie propri\u00e9taire C-StemTM<\/sup>\u00a0, TreeFrog Therapeutics a produit un lot de 15 milliards de cellules en 6,5 jours en partant de 50 millions de cellules. La soci\u00e9t\u00e9 rapporte \u00e9galement une qualit\u00e9 cellulaire exceptionnelle. Les donn\u00e9es seront pr\u00e9sent\u00e9es lors de l’International Society for Stem Cell Research (ISSCR) Virtual Meeting<\/a>, qui se tiendra du 21 au 26 juin 2021.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"C-Stem\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

A scalable approach to overcome the limitations of 2D cell\u00a0<\/span><\/b>culture<\/span><\/b>\u00a0<\/span><\/h4>\n

With a 151 millionfold cumulated amplification, C-<\/span>Stem<\/span>\u2122<\/span> nearly doubles the performance of 2D culture.<\/span>\u00a0<\/span><\/p>\n

\u201c<\/span>Traditionally,<\/span>\u00a0pluripotent stem cells\u00a0<\/span>are grown\u00a0<\/span>in 2D, at the bottom of Petri dishes<\/span>,<\/span>\u201d\u00a0<\/span>said Maxime Feyeux,\u00a0<\/span>c<\/span>o-founder and Chief Scientific Officer of TreeFrog Therapeutics.<\/span>\u00a0<\/span>\u201c<\/span>And while\u00a0<\/span>2D enabled the launch of the first trials with\u00a0<\/span>iPS<\/span>-derived therapeutic cells, this technology now constitutes a critical bottleneck for <\/span>cell therapy manufacturing<\/span>\u00a0because of its\u00a0<\/span>inherent\u00a0<\/span>limitations in scaling<\/span>. 2D cell culture\u00a0<\/span>is expensive and lacks reproducibility at a <\/span>commercial<\/span>\u00a0scale because of the<\/span> labor, time, and space<\/span>\u00a0it requires.\u00a0<\/span>For instance,\u00a0<\/span>to produce the batch of 15 billion cells that we recently announced, <\/span>it would require\u00a0<\/span>ramping to\u00a0<\/span>4\u00a0<\/span>full-time staff<\/span>\u00a0<\/span>over 2 weeks and <\/span>hundreds of<\/span>\u00a0<\/span>P<\/span>etri dishes<\/span>, whereas it took us 2\u00a0<\/span>staff<\/span>\u00a0<\/span>for less than a week\u00a0<\/span>and a single <\/span>10L\u00a0<\/span>bioreactor<\/span>\u00a0with C-<\/span>Stem<\/span>\u2122<\/span>.<\/span>\u201d<\/span>\u00a0<\/span>\u00a0<\/span><\/p>\n

Scale-up in bioreactors \u2013 C-<\/span><\/b>Stem<\/span><\/b>\u2122\u00a0leapfrogs aggregate culture\u00a0<\/b><\/span>\u00a0<\/span><\/h4>\n

Over 28<\/span>\u00a0<\/span>day<\/span>s<\/span>,\u00a0<\/span>a<\/span>\u00a013,330-fold amplification<\/span>\u00a0was observed<\/span>\u00a0with\u00a0<\/span>hiPSC<\/span> aggregates in bioreactors<\/span>, with<\/span>\u00a0<\/span>six<\/span>\u00a0passages, while\u00a0<\/span>a\u00a0<\/span>151<\/span>\u00a0<\/span>millionfold amplification was obtained with C-<\/span>Stem<\/span>\u2122<\/span>\u00a0in\u00a0<\/span>four<\/span>\u00a0passages.\u00a0<\/span>\u00a0<\/span><\/p>\n

\u201cI believe\u00a0<\/span>two\u00a0<\/span>core factors explain such a difference in yield<\/span>,<\/span>\u201d\u00a0<\/span>said Kevin Alessandri, co-founder and Chief <\/span>Technical<\/span>\u00a0Officer of TreeFrog Therapeutics.<\/span>\u00a0<\/span>\u201cOn the o<\/span>ne hand, our cell encapsulation technology is protecting the cells from impeller-induced shear stress in bioreactors, therefore <\/span>limiting in-process cell death<\/span>. On the other,\u00a0<\/span>the biomimetic microenvironment that we engineered inside the capsule <\/span>allows<\/span>\u00a0<\/span>h<\/span>iPSCs<\/span>\u00a0to self-organize into a<\/span>n<\/span>\u00a0empty-core epiblast-like structure<\/span>\u00a0promoting<\/span>\u00a0fast and high-fidelity cell division,\u00a0<\/span>thus<\/span>\u00a0contrast<\/span>ing<\/span>\u00a0with\u00a0<\/span>the necrotic core found in aggregates<\/span>.<\/span>\u201d<\/span>\u00a0<\/span>\u00a0<\/span><\/p>\n

Benefits in\u00a0<\/span><\/b>genomic quality to be further\u00a0<\/span><\/b>investigated<\/span><\/b>\u00a0<\/span><\/h4>\n

The b<\/span>enchmark data\u00a0<\/span>show<\/span>s<\/span>\u00a0<\/span>that<\/span>\u00a0final cell viability and pluripotency\u00a0<\/span>are comparable <\/span>across the different cell culture systems.\u00a0<\/span><\/p>\n

\u201c<\/span>However, our<\/span>\u00a0preliminary results<\/span>\u00a0<\/span>suggest<\/span>\u00a0<\/span>that C-<\/span>Stem<\/span>\u2122<\/span>\u00a0is the only technology\u00a0<\/span>with the potential of maintaining genomic integrity<\/span>\u00a0<\/span>throughout large-scale <\/span>hiPSC<\/span>\u00a0<\/span>expansion<\/span>,\u201d said Feyeux.<\/span>\u00a0<\/span>\u201c<\/span>In the coming months, we\u2019ll investigate the benefits of C-<\/span>Stem<\/span>\u2122<\/span>\u00a0<\/span>with\u00a0<\/span>the QC-Stem\u00a0<\/span>C<\/span>onsortium, which brings together<\/span> experts in clinical- grade <\/span>hiPSC<\/span>\u00a0quality control from<\/span> the Harvard Stem Cell Institute<\/span>\u00a0in Boston, USA, the FBRI in Kobe Japan, and the Imagine Institute in Paris, France<\/span>.<\/span>\u201d<\/span>\u00a0<\/span><\/p>\n

About TreeFrog Therapeutics<\/span><\/b>\u00a0<\/span><\/h4>\n

TreeFrog Therapeutics is a\u00a0<\/span>startup<\/span>\u00a0company aiming at providing access to cell therapies for millions of patients. TreeFrog Therapeutics has developed
C-<\/span>Stem<\/span>\u2122<\/span>, a high-throughput cell encapsulation technology allowing<\/span>\u00a0for<\/span>\u00a0the mass-production and differentiation of stem cells in industrial bioreactors. This proprietary technology platform provides an end-to-end and scalable solution that dramatically improve<\/span>s<\/span>\u00a0the quality of therapeutic cells and reduce treatment costs.<\/span>\u00a0<\/span><\/p>\n

Since its incorporation in November 2018 in Bordeaux, France, TreeFrog Therapeutics has experienced strong acceleration, raising over \u20ac13M ($<\/span>15<\/span>.<\/span>6<\/span>0<\/span>M) in 2019. In January 2020, TreeFrog Therapeutics joined the FrenchTech120, an elite programme for the fastest-growing technology companies in France. The team<\/span>\u2014<\/span>currently\u00a0<\/span>40<\/span>+<\/span>\u00a0<\/span>employees<\/span>\u2014<\/span>moved into a brand-new production facility of 13,000\u00a0<\/span>sq<\/span>\u00a0ft in June 2020.<\/span>\u00a0In October 2020, TreeFrog Therapeutics was awarded the Prix\u00a0<\/span>Galien<\/span>\u00a0<\/span>MedStartup<\/span> for its international consortium on iPSC quality with the Harvard Stem Cell Institute, the FRBI in Kobe (Japan) and the Imagine Institute in Paris (France).\u00a0<\/span>\u00a0<\/span><\/p>\n

www.treefrog.fr<\/a><\/span><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\"European\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

TreeFrog Therapeutics is receiving funding from the European Union\u2019s Horizon 2020 research and innovation program through the SME Instrument Phase 2 under grant agreement n\u00b0 SME 881113.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Press Contacts<\/strong><\/p>

TreeFrog Therapeutics
<\/strong>Pierre-Emmanuel Gaultier \u2013 pierre@treefrog.fr<\/a> \u2013 +336 4577 4258<\/p>

Download picture<\/span><\/a><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

La technologie biomim\u00e9tique de TreeFrog Therapeutics repousse les limites de la production industrielle de th\u00e9rapies cellulaires issues de cellules souches. La soci\u00e9t\u00e9 vient de produire un lot de 15 milliards de cellules souches, avec une croissance exponentielle in\u00e9dite dans des bior\u00e9acteurs de 10 litres, tout…<\/p>\n","protected":false},"author":1,"featured_media":2053,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[12,13],"tags":[],"aioseo_notices":[],"yoast_head":"\nC-Stem\u2122 outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells - TreeFrog Therapeutics I iPS-derived cell therapies<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C-Stem\u2122 outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells - TreeFrog Therapeutics I iPS-derived cell therapies\" \/>\n<meta property=\"og:description\" content=\"La technologie biomim\u00e9tique de TreeFrog Therapeutics repousse les limites de la production industrielle de th\u00e9rapies cellulaires issues de cellules souches. La soci\u00e9t\u00e9 vient de produire un lot de 15 milliards de cellules souches, avec une croissance exponentielle in\u00e9dite dans des bior\u00e9acteurs de 10 litres, tout...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/\" \/>\n<meta property=\"og:site_name\" content=\"TreeFrog Therapeutics I iPS-derived cell therapies\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-11T13:10:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-20T14:46:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/preprod.treefrog.fr\/wp-content\/uploads\/2021\/05\/TreeFrog-Therapeutics-exponential-iPS-cell-expansion-in-large-scale-bioreactor-preserved-cell-quality.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Piergueritona\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/\",\"url\":\"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/\",\"name\":\"C-Stem\u2122 outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells - TreeFrog Therapeutics I iPS-derived cell therapies\",\"isPartOf\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/#website\"},\"datePublished\":\"2021-05-11T13:10:00+00:00\",\"dateModified\":\"2021-07-20T14:46:37+00:00\",\"author\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220\"},\"breadcrumb\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/preprod.treefrog.fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C-Stem\u2122 outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#website\",\"url\":\"https:\/\/preprod.treefrog.fr\/\",\"name\":\"TreeFrog Therapeutics I iPS-derived cell therapies\",\"description\":\"Cell Therapy for All\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/preprod.treefrog.fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220\",\"name\":\"Piergueritona\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g\",\"caption\":\"Piergueritona\"},\"sameAs\":[\"https:\/\/preprod.treefrog.fr\"],\"url\":\"https:\/\/preprod.treefrog.fr\/author\/piergueritona\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"C-Stem\u2122 outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells - TreeFrog Therapeutics I iPS-derived cell therapies","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"C-Stem\u2122 outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells - TreeFrog Therapeutics I iPS-derived cell therapies","og_description":"La technologie biomim\u00e9tique de TreeFrog Therapeutics repousse les limites de la production industrielle de th\u00e9rapies cellulaires issues de cellules souches. La soci\u00e9t\u00e9 vient de produire un lot de 15 milliards de cellules souches, avec une croissance exponentielle in\u00e9dite dans des bior\u00e9acteurs de 10 litres, tout...","og_url":"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/","og_site_name":"TreeFrog Therapeutics I iPS-derived cell therapies","article_published_time":"2021-05-11T13:10:00+00:00","article_modified_time":"2021-07-20T14:46:37+00:00","og_image":[{"width":2048,"height":1365,"url":"https:\/\/preprod.treefrog.fr\/wp-content\/uploads\/2021\/05\/TreeFrog-Therapeutics-exponential-iPS-cell-expansion-in-large-scale-bioreactor-preserved-cell-quality.jpg","type":"image\/jpeg"}],"author":"Piergueritona","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/","url":"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/","name":"C-Stem\u2122 outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells - TreeFrog Therapeutics I iPS-derived cell therapies","isPartOf":{"@id":"https:\/\/preprod.treefrog.fr\/#website"},"datePublished":"2021-05-11T13:10:00+00:00","dateModified":"2021-07-20T14:46:37+00:00","author":{"@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220"},"breadcrumb":{"@id":"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/preprod.treefrog.fr\/c-stem-outperforms-2d-aggregate-cultures-in-benchmark-of-cell-culture-technologies-for-the-mass-production-of-human-induced-pluripotent-stem-cells\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/preprod.treefrog.fr\/"},{"@type":"ListItem","position":2,"name":"C-Stem\u2122 outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells"}]},{"@type":"WebSite","@id":"https:\/\/preprod.treefrog.fr\/#website","url":"https:\/\/preprod.treefrog.fr\/","name":"TreeFrog Therapeutics I iPS-derived cell therapies","description":"Cell Therapy for All","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/preprod.treefrog.fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220","name":"Piergueritona","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g","caption":"Piergueritona"},"sameAs":["https:\/\/preprod.treefrog.fr"],"url":"https:\/\/preprod.treefrog.fr\/author\/piergueritona\/"}]}},"_links":{"self":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts\/2087"}],"collection":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/comments?post=2087"}],"version-history":[{"count":6,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts\/2087\/revisions"}],"predecessor-version":[{"id":2561,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts\/2087\/revisions\/2561"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/media\/2053"}],"wp:attachment":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/media?parent=2087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/categories?post=2087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/tags?post=2087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}